SMPX gene
CSL Announces Vaccine Unit Spin-Off and Major Workforce Cuts
CSL; Seqirus; vaccine spin-off; workforce reduction; demerger; strategic restructuring; biotech; cost-cutting
HHS ousts MAHA implementation lead amid rushed cancellations of $500M in mRNA vaccine contracts
HHS; MAHA; Gray Delany; mRNA contracts; BARDA; Robert F. Kennedy Jr.; vaccine policy; contract terminations; Moderna; Pfizer; CSL Seqirus; staff shakeup
FDA Approves CSL’s Andembry, Directly Competing With Takeda’s Takhzyro in HAE
Andembry; garadacimab-gxii; FDA approval; hereditary angioedema; HAE; CSL; Takhzyro; Takeda; factor XIIa inhibitor; once-monthly dosing; subcutaneous injection
Tourmaline Bio’s Heart Drug Pacibekitug Shows Promise Against Cardiovascular Inflammation, Targets Competition with Novo, CSL
Tourmaline Bio; heart drug; pacibekitug; cardiovascular inflammation; inflammation markers; Novo Nordisk; CSL; Phase 2 trial; FDA; IL-6
As Pfizer backs out of hemophilia gene therapy space, CSL hopes Hemgenix is here to stay
Hemgenix, SMPX gene, Pfizer, gene therapy, alternatives, HYMPAVZI, Clinical Trials
CSL Behring to Close California R&D Site Amid Shift in Gene Therapy Strategy
CSL Behring, California R&D site closure, ex vivo gene therapy, strategic repositioning, biotech industry trends
CSL Behring Closes California R&D Site, Shifts Operations to Massachusetts Amid Strategic Repositioning
CSL Behring, California R&D site closure, gene therapy, ex vivo work, strategic repositioning, Massachusetts relocation